BRAF-mutated colorectal adenocarcinoma
Monday 15 May 2017
BRAF-mutated colorectal carcinoma
BRAF-mutated MSI colorectal carcinoma
In a study, no evidence existed for a differential prognostic role of BRAF mutation by MSI status (P(interaction) > .50). (23878352)
Combined BRAF/MSI status in colorectal cancer is a tumor molecular biomarker for prognosic risk stratification.
Reduced CDX2 and cytokeratin 20 (CK20) expression in colorectal carcinoma with BRAF mutation and high-level microsatellite instability (MSI-H) has been documented.
BRAF-mutated MSS colorectal carcinoma
BRAF-mutated MSS colorectal carcinoma often displays reduced CDX2 and increased CK7 expression. (24908142)
Knowledge of this altered immunophenotype is important as patients with BRAF-mutated MSS colorectal carcinoma often present with metastatic disease.
The altered tumor immunophenotype may lead to the erroneous assumption that origin from the colon/rectum is unlikely.
Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, Qian ZR, Morikawa T, Shen J, Meyerhardt JA, Fuchs CS, Ogino S. J Natl Cancer Inst. 2013 Aug 7;105(15):1151-6. doi : 10.1093/jnci/djt173
PMID: 23878352 Free
BRAF-mutated microsatellite stable colorectal carcinoma: an aggressive adenocarcinoma with reduced CDX2 and increased cytokeratin 7 immunohistochemical expression. Landau MS, Kuan SF, Chiosea S, Pai RK. Hum Pathol. 2014 Aug;45(8):1704-12. doi : 10.1016/j.humpath.2014.04.008 PMID: 24908142